2003
DOI: 10.1016/s0926-6410(03)00199-x
|View full text |Cite
|
Sign up to set email alerts
|

Altered auditory processing in acutely psychotic never-medicated first-episode patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

8
41
3

Year Published

2007
2007
2017
2017

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 63 publications
(52 citation statements)
references
References 84 publications
8
41
3
Order By: Relevance
“…This fact, suggests that in the last decades N1 and N2 components have been studied as possible endophenotypes or bio-markers for different disorders and in some cases for recovery index: namely, in schizophrenia (Hegerl et al 1988;Haig et al 1997;Potts et al 1998a;Shelley et al 1999;Ford et al 2001;Brown et al 2002;Gilmore et al 2005;Neuhaus et al 2013), dementia (Verma et al 1989), Alzheimer (Sumi et al 2000), epilepsy and AED effects (Akaho 1996;Ford et al 2001;Lucchesi et al 2003), alcohol (Brigham et al 1997;Cohen et al 2002) and substance abuse (Tarter et al 1995;Brigham et al 1997), psychosis (Valkonen-Korhonen et al 2003), panic disorder (Wise et al 2009), Parkinson's disease (Wright et al (1996), ADHD (Johnstone et al 2001;Tsai et al 2012), stroke (Hirata et al 1996) and vascular cognitive impairment (van Harten et al 2006), myotonic dystrophy (Kazis et al 1996;Tanaka et al 2012), head injury (Reinvang et al 2000;Segalowitz et al 2001), (Guney et al 2009), amyotrophic lateral sclerosis (Ogawa et al 2009) and multiple sclerosis (Whelan et al 2010), more recently fragile X syndrome treatment (Schneider et al 2013), and bipolar disorder (Hamm et al 2013). …”
Section: Discussionmentioning
confidence: 99%
“…This fact, suggests that in the last decades N1 and N2 components have been studied as possible endophenotypes or bio-markers for different disorders and in some cases for recovery index: namely, in schizophrenia (Hegerl et al 1988;Haig et al 1997;Potts et al 1998a;Shelley et al 1999;Ford et al 2001;Brown et al 2002;Gilmore et al 2005;Neuhaus et al 2013), dementia (Verma et al 1989), Alzheimer (Sumi et al 2000), epilepsy and AED effects (Akaho 1996;Ford et al 2001;Lucchesi et al 2003), alcohol (Brigham et al 1997;Cohen et al 2002) and substance abuse (Tarter et al 1995;Brigham et al 1997), psychosis (Valkonen-Korhonen et al 2003), panic disorder (Wise et al 2009), Parkinson's disease (Wright et al (1996), ADHD (Johnstone et al 2001;Tsai et al 2012), stroke (Hirata et al 1996) and vascular cognitive impairment (van Harten et al 2006), myotonic dystrophy (Kazis et al 1996;Tanaka et al 2012), head injury (Reinvang et al 2000;Segalowitz et al 2001), (Guney et al 2009), amyotrophic lateral sclerosis (Ogawa et al 2009) and multiple sclerosis (Whelan et al 2010), more recently fragile X syndrome treatment (Schneider et al 2013), and bipolar disorder (Hamm et al 2013). …”
Section: Discussionmentioning
confidence: 99%
“…Similar to MMN, it may be that users do not utilise neural resources efficiently (Ramaekers et al 2009;Battisti et al 2010a;Battisti et al 2010b), and this is reflected by a delayed P3a latency. Alternatively, given that the latencies and peak amplitudes of MMN and P3a components increase sequentially when they are measured concurrently (Valkonen-Korhonen et al 2003;Javitt et al 2008), prolonged P3a latencies may be a consequence of an already delayed MMN latency.…”
Section: Discussionmentioning
confidence: 99%
“…A second limitation may be the use of overlapping windows for MMN and P3a components particularly during peak selection. However, latencies and peak amplitudes of MMN and P3 components increase sequentially when they are measured concurrently (ValkonenKorhonen et al 2003;Javitt et al 2008), safeguarding against incorrect peak selection (Valkonen-Korhonen et al 2003).…”
Section: Discussionmentioning
confidence: 99%
“…In line with this, pharmacological studies suggest MMN reflects glutamatergic processes [60,61], whereas P3a amplitude is modulated by dopamine (and hence current anti-psychotic medications) [62,63]. Consistent with the findings for MMN, P3a amplitude correlates with cognitive and psychosocial functioning [59,64,65], and is reduced in schizophrenia [59,66], first episode psychosis [37, 41,64,67], and in at risk samples [36,37,39,41]. Thus P3a might provide an additional biomarker for psychosis but targeting different disease processes, and can be readily measured concurrently with MMN.…”
Section: The P3amentioning
confidence: 56%